Roche sounds another warning over co-stimulation
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
Replimune’s fight with the FDA deepens
The oncolytic virus vuso-vec is slapped with its second CRL.
Bicycle finally falls
The company admits defeat with zelenectide.
